English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  Inflammation and oxidative stress are recognized as important contributors to Parkinson’s disease pathogenesis. As such, genetic variability in these pathways could have a role in susceptibility for the disease as well as in the treatment outcome. Dopaminergic treatment is effective in management of motor symptoms, but poses a risk for motor and non-motor adverse events. Our aim was to evaluate the impact of selected single-nucleotide polymorphisms in genes involved in inflammation and oxidative stress on Parkinson’s disease susceptibility and the occurrence of adverse events of dopaminergic treatment.    Methods  In total, 224 patients were enrolled, and their demographic and clinical data on the disease course were collected. Furthermore, a control group of 146 healthy Slovenian blood donors were included for Parkinson’s disease’ risk evaluation. Peripheral blood was obtained for DNA isolation. Genotyping was performed for  NLRP3  rs35829419,  CARD8  rs2043211,  IL1β  rs16944,  IL1β  rs1143623,  IL6  rs1800795,  CAT  rs1001179,  CAT  rs10836235,  SOD2  rs4880,  NOS1  rs2293054,  NOS1  rs2682826,  TNF-α  rs1800629, and  GPX1  rs1050450. Logistic regression was used for analysis of possible associations.    Results  We observed a nominally significant association of the  IL1β  rs1143623 C allele with the risk for Parkinson’s disease  ( OR = 0.59; 95%CI = 0.38–0.92,  p  = 0.021).  CAT  rs1001179 A allele was significantly associated with peripheral edema (OR = 0.32; 95%CI = 0.15–0.68;  p  = 0.003). Other associations observed were only nominally significant after adjustments:  NOS1  rs2682826 A allele and excessive daytime sleepiness and sleep attacks (OR = 1.75; 95%CI = 1.00–3.06,  p  = 0.048),  SOD2  rs4880 T allele and nausea/vomiting (OR = 0.49, 95%CI = 0.25–0.94;  p  = 0.031),  IL1β  rs1143623 C allele and orthostatic hypotension (OR = 0.57, 95%CI = 0.32–1.00,  p  = 0.050), and  NOS1  rs2682826 A allele and impulse control disorders (OR = 2.59; 95%CI = 1.09–6.19;  p  = 0.032). We did not find any associations between selected polymorphisms and motor adverse events.    Conclusions  Apart from some nominally significant associations, one significant association between  CAT  genetic variability and peripheral edema was observed as well. Therefore, the results of our study suggest some links between genetic variability in inflammation- and oxidative stress-related pathways and non-motor adverse events of dopaminergic treatment. However, the investigated polymorphisms do not play a major role in the occurrence of the disease and the adverse events of dopaminergic treatment.    Electronic supplementary material  The online version of this article (10.1186/s12974-019-1439-y) contains supplementary material, which is available to authorized users.

journal of neuroinflammation

Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson’s disease